BioSpace News Archive

Nature’s Toolbox (NTx), a biomanufacturing and bioinformatics company, today announced the appointment of Joseph Sullivan as Chief Commercial Officer to advance the go-to-market strategy for its novel biological manufacturing and development platform following a series of major milestones over the past year.

PRC, a leader in healthcare experience solutions, announced today significant findings from their 2020 National Health Survey focused on senior citizens living in the US.

Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the European Medicines Agency (EMA) human medicines committee (CHMP) has started a rolling review of mRNA-1273,

Celularity, Inc., a clinical-stage cell therapeutics company focused on the development of innovative allogeneic placenta-derived cellular therapies, announced today the addition of two senior executives to its distinguished leadership team.

Olive Pro’s modern design, unmatched pricing and smart AI technology is the ultimate hearing aids killer, offering affordable hearing for all.

Palladio Biosciences, Inc. (Palladio), a privately-owned, clinical stage biopharmaceutical company developing medicines for orphan diseases of the kidney, today announced that the first patient has been dosed with lixivaptan, a novel vasopressin V2 antagonist, in The ALERT Study. The ALERT Study, designed to assess the safety of lixivaptan in autosomal dominant polycystic kidney disease (ADPKD) patients who previously

Pharma Logistics and ConsortiEX, market leaders in serving the needs of pharmacies and hospitals, today announced the launch of their Strategic Collaboration Program.

Eight-year Collaboration with UN Foundation has Provided 60 Million Immunizations to Vulnerable Populations Around the World

Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells within the patient’s body, provided a business update for the third quarter of 2020.

BeyondSpring Inc., a global biopharmaceutical company focused on the development of innovative cancer therapies, announced the launch of an underwritten public offering of $75 million of its ordinary shares.